Vor Biopharma Inc. (VOR)
$4.49
+0.22 (+5.15%)
Rating:
Recommendation:
-
Symbol | VOR |
---|---|
Price | $4.49 |
Beta | 0.000 |
Volume Avg. | 0.10M |
Market Cap | 168.817M |
Shares () | - |
52 Week Range | 4.01-23.535 |
1y Target Est | - |
DCF Unlevered | VOR DCF -> | |
---|---|---|
DCF Levered | VOR LDCF -> | |
ROE | -26.70% | Sell |
ROA | -25.47% | Sell |
Operating Margin | - | |
Debt / Equity | 20.48% | Neutral |
P/E | - | |
P/B | 0.86 | Buy |
Latest VOR news
About
Download (Excel)Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.